{"id":"NCT03048747","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH","officialTitle":"A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-02","primaryCompletion":"2019-03-19","completion":"2019-03-19","firstPosted":"2017-02-09","resultsPosted":"2020-11-02","lastUpdate":"2020-11-02"},"enrollment":16,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Syndrome of Inappropriate Antidiuretic Hormone Secretion"],"interventions":[{"type":"DRUG","name":"Tolvaptan Oral Tablet","otherNames":[]}],"arms":[{"label":"Tolvaptan","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in patients with hyponatremia in the SIADH.","primaryOutcome":{"measure":"Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration","timeFrame":"Baseline, Day2, Day3, Day4, Day5, Day7, Day14, Day21, Day after final study medication","effectByArm":[{"arm":"Tolvaptan","deltaMin":43.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":16},"commonTop":["Thirst","Decreased appetite","Neutropenia","Constipation","Nausea"]}}